FDA approves Elevar Therapeutics' Lyrfigtu for bile duct cancer with FGFR2 alterations

Overview Debates Related claims Topics Sources

Geraldine Levano reached more than three years of cancer remission following her stage 3 colorectal cancer treatments.

Radon is the second leading cause of lung cancer after smoking, causing an estimated 21,000 deaths annually

Mass General Brigham Cancer Institute will offer services across eight cancer specialties, including gastrointestinal and thoracic oncology, by November 2026, MGB said

In the Sungkyunkwan University cohort, each 1-unit increase in biological age acceleration based on nine routine blood markers was associated with a 7% higher risk of early-onset colorectal adenocarcinoma.

The original version of Freenome's blood-based SimpleScreen CRC screening test is already FDA-approved for colorectal cancer surveillance.

A study found advanced stage at diagnosis accounted for 24.9% of excess rural breast cancer deaths, while radiation omission and chemotherapy omission accounted for 11.4% and 7.9% respectively.

The American College of Obstetricians and Gynecologists guidelines recommend systemic hormone replacement therapy with estrogen and progestogen for women with a uterus to mitigate endometrial cancer risk from estrogen-stimulated uterine lining growth, or estrogen alone without

The transaction includes BioReference Health's proprietary 4Kscore test, an FDA-approved blood test used to evaluate the likelihood of aggressive prostate cancer prior to a biopsy.

Glioblastoma is a significant topic in the health domain with ongoing developments and regulatory implications.

Moderna's personalized mRNA melanoma vaccine cuts cancer recurrence risk by half in five-year trial results

FDA Oncology Center of Excellence director R. Angelo de Claro stated that review of shared cancer features allowed the agency to expand treatment options for papillary tumors

In 1984, while living in Rome, the future Pope Leo XIV wrote to friends regarding his mother's ongoing chemotherapy treatments in Chicago

Oncologists recommend that lung surgery patients refrain from flying for three weeks following an operation

Breast cancer screening guidelines should be expanded to include women under age 40

Healthcare provider bias is the primary cause of diagnostic delays in young breast cancer patients

Pretreatment circulating tumor cell levels are a reliable basis for selecting breast cancer patients for ablation

Caribou Biosciences' vispa-cel, a Phase 3-ready allogeneic CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma, has a Food and Drug Administration-agreed pivotal Phase 3 trial design.

Dr. Imogen Brooks was diagnosed with squamous cell carcinoma, the most common type of head and neck cancer, at the age of 26.

In the Phase 1 ANTLER trial, vispa-cel demonstrated an 82% overall response rate and a 67% complete response rate in patients with second-line large B cell lymphoma.

In England, prostate cancer diagnoses among men under 50 quadrupled from one per 100,000 in 2001 to 3.6 per 100,000 in 2023, with annual cases rising from 158 to 640.